Are concerns about reliability in the trial to assess chelation therapy fair grounds for a hasty dismissal?: An alternative perspective.

Trial to Assess Chelation Therapy (TACT) was a prospective, randomized, double-blind, placebo-controlled trial designed to evaluate the effect of ethylenediaminetetraacetic acid-based intravenous chelation therapy on cardiovascular outcomes. A total of 1708 stable patients >50 years of age with a previous myocardial infarction were enrolled at 134 North American sites and followed for a median of 55 months. The overall results showed that chelation therapy reduced the risk of primary major adverse cardiac events plus end point— a composite of death, myocardial infarction, stroke, coronary revascularization, or hospitalization for angina.